Benralizumab associated with histologic response in eosinophilic esophagitis
1. In this randomized controlled trial, benralizumab, an anti-interleukin-5 receptor (anti-IL-5R) monoclonal antibody, demonstrated histologic depletion of eosinophils among patients with eosinophilic esophagitis (EoE) compared to placebo. 2. Patients receiving...